Function
Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.
Osimertinib Mesylate (CAS 1421373-66-1) is a pharmaceutical grade API used as a third-generation EGFR tyrosine kinase inhibitor. Its molecular formula is C28H33F3N6O4S, synthesized via precise organic coupling and salt formation processes.
Strictly store below 25°C in dry, light-resistant conditions. Handle with PPE to avoid inhalation or skin contact; contraindicated in pregnancy without specialist consultation.